Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002368 · ClinicalTrials.gov registry record · Phase 3

The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV Drugs

A Phase 3 study of HIV Infections, sponsored by Boehringer Ingelheim.

Completed
Registry status
Phase 3
Development phase
2,000
Enrollment target
20
Study locations

NCT00002368: Completed Phase 3 study of HIV Infections, sponsored by Boehringer Ingelheim.

NCT00002368 is a Phase 3 study of HIV Infections that has completed, run by Boehringer Ingelheim. The registered enrollment target is 2,000 participants, above the 442-participant average among 542 other HIV Infections trials with a reported enrollment target (352% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002368, a Phase 3 study of HIV Infections, has completed, sponsored by Boehringer Ingelheim.

COMPLETED
Registry status
Phase 3
Development phase
2,000 participants
Enrollment target
20
Study locations

Study Summary

To evaluate the tolerance, safety, and effectiveness of Viramune in preventing clinical AIDS progression events or death when used in combination with Lamivudine and background nucleoside therapy.

Conditions Studied

HIV Infections

Interventions

  • DRUG Lamivudine
  • DRUG Nevirapine

Study Locations (20)

California

  • Dr G Michael Wool - Los Angeles
  • UCLA School of Medicine / Ctr for Research and Education - Los Angeles
  • AIDS Research Ctr / Palo Alto VA Health Care System - Palo Alto
  • AIDS Community Research Consortium - Redwood City
  • ViRx Inc - San Francisco
  • San Francisco Gen Hosp / UCSF AIDS Program - San Francisco
  • Harbor - UCLA Med Ctr - Torrance

Florida

  • Anthony LaMarca - Fort Lauderdale
  • North Broward Hosp District - Fort Lauderdale
  • Dr Robert Schwartz - Fort Myers
  • McGregor Clinic / Lee County Public Health Unit - Fort Myers
  • P Andrew Coley - Jacksonville
  • Goodgame Med Group - Maitland
  • Infectious Disease Research Institute Inc - Tampa

Colorado

  • Infectious Disease Specialists - Colorado Springs
  • Denver Public Health - Denver
  • Dr Miguel Mogyoros / Clinical Research Dept - Denver

Alabama

  • Drug Research and Analysis Corp - Montgomery

Delaware

  • Wilmington Hosp - Wilmington

District of Columbia

  • Novum Inc - Washington D.C.

Trial Details

FieldValue
Enrollment Target 2,000 participants
Phase Phase 3
Boehringer Ingelheim

515 total trials

What the finished NCT00002368 record still lists

NCT00002368 is an interventional study that assigns participants to a tested intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 442-participant average among 542 other HIV Infections trials with a reported enrollment target (352% higher).

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Lamivudine is the first listed.

NCT00002368 names 20 study sites across 6 states, led by California, Florida, Colorado.

Frequently Asked Questions

What is clinical trial NCT00002368 about?

NCT00002368 is a clinical study titled "The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV Drugs". To evaluate the tolerance, safety, and effectiveness of Viramune in preventing clinical AIDS progression events or death when used in combination with Lamivudine and background nucleoside therapy.

What is the current status of trial NCT00002368?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,000 participants.

What conditions does trial NCT00002368 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00002368?

The interventions under investigation include: Lamivudine (DRUG), Nevirapine (DRUG).

Who is sponsoring clinical trial NCT00002368?

This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002368 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Delaware, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00002368's enrollment target sits among peer trials

2,000 12th of 542 higher than 531 of 542 other HIV Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001465 · 2,000 participants

    Study of the Disease Process of Lymphangioleiomyomatosis

  • NCT00001595 · 2,000 participants

    An Investigation of Pituitary Tumors and Related Hypothalmic Disorders

  • NCT00138931 · 2,000 participants

    Genetics of Cardiovascular and Neuromuscular Disease

  • NCT00288119 · 2,000 participants

    Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma

Related registry views

Source: ClinicalTrials.gov NCT00002368, the US trial registry maintained by the National Library of Medicine. NCT00002368 (large enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.